Valeant Seeking Return To Growth With New Chief Executive
This article was originally published in The Pink Sheet Daily
Executive Summary
Valeant names J. Michael Pearson, who with McKinsey & Co. assisted in reorganization, firm tells “The Pink Sheet” DAILY.
You may also be interested in...
GSK And Valeant Partner On Epilepsy Candidates
$125 million upfront deal could ameliorate impact of 2010 Lamictal patent expiry for GSK.
GSK And Valeant Partner On Epilepsy Candidates
$125 million upfront deal could ameliorate impact of 2010 Lamictal patent expiry for GSK.
Valeant Will Trim Its Focus To North America, Concentrate On Neurology And Dermatology
Firm also plans to partner lead candidates retigabine and taribavirin, new CEO Pearson says.